Chick Embryo Cell Rabies Vaccine Market

Chick Embryo Cell Rabies Vaccine Market Outlook (2024 to 2034)

The global chick embryo cell rabies vaccine market is approximated to reach a worth of US$ 1.42 billion in 2024 and further expand at a significant CAGR of 6% to touch a size of US$ 2.55 billion by the end of 2034.

Demand for chick embryo cell rabies vaccine is increasing as people are increasingly becoming aware of rabies prevention in both humans and animals. Several governments are launching an ample number of public health campaigns and educational activities to spread knowledge about the danger of rabies and the effectiveness of vaccination to fight this disease.

International Aid Organization is working effectively to control rabies symptoms by providing financial and technical support to countries with high rabies cases, including those made using chick embryo cells. Added to aid organizations, medical tourism is also lifting its popularity, contributing to the growing demand for rabies vaccine, particularly for individuals heading to regions where rabies is still too prevalent. This is giving perfect exposure for vaccine manufacturers to establish their businesses and generate good profits.

Continuous improvements in vaccine production and cell structure are allowing rabies patients to get safer and more effective vaccines. This is making the demand escalate for chick embryo cell-based vaccines to be more reliable and widely adopted by patients, especially in mass vaccination programs.

Chick embryo cell culture is more cost-effective compared to other traditional methods, which is one of the other reasons for the accelerating demand for these vaccines. This reason is making chick embryo cell rabies vaccine a more accessible and affordable option, especially in resource-limited regions, therefore driving the market growth.

North America is forecasted to hold 37% of the worldwide chick embryo cell rabies vaccine market share in 2024, with the United States and Canada acting as a key player. While rabies is largely controlled in the above countries with the help of effective vaccination programs, vaccines are still prominently in demand for pre-exposure prophylaxis for travelers to rabies-endemic regions and for individuals involved in high-risk occupations, such as animal handling.

Report Attribute	Detail
Chick Embryo Cell Rabies Vaccine Market Size (2024E)	US$ 1.42 Billion
Forecasted Market Value (2034F)	US$ 2.55 Billion
Global Market Growth Rate (2024 to 2034)	6% CAGR
North America Market Share (2024E)	37%
East Asia Market Value (2024E)	US$ 251.14 Million
South Asia & Pacific Market Growth Rate (2024 to 2034)	7.3% CAGR
Post-exposure Prophylaxis (Intra-Muscular) Segment Value (2034F)	US$ 1.69 Billion
Hospital Pharmacies Segment Value (2034F)	US$ 1.32 Billion
Key Companies Profiled	Sanofi Pasteur; Baxter International; Merck & Co., Inc.; GlaxoSmithKline (GSK); Indian Immunologicals Ltd.; Haffkine Bio-Pharmaceutical Corporation; Vaccine Research Center (VRC); Serum Institute of India; Biological E. Limited; Kaketsuken Co., Ltd.

Rabies is a disease caused by Rabies virus. There are so many types of vaccines but the chick embryo cell rabies vaccine is a sterilized vaccine synthesized by growing a fixed strain of rabies virus strain Flury LEP-25. Chick embryo cell rabies vaccine are obtained from primary cultures of chick fibroblasts.

The virus is purified and then concentrated using the zonal centrifugation technique and is inactivated with ß-propiolactone. Purified chick embryo cell vaccine (PCECV) or chick embryo cell rabies vaccine is a product produced by complex batch-wise manufacturing procedures.

As per WHO (World Health Organization) chick embryo rabies, vaccine is 100% efficacious and has helped in saving millions of lives since the 80’s. Chick embryo cell rabies vaccine produced from several different types of cell substrates, such as nerve tissue rabies vaccine are rapidly being replaced by chick embryo cell rabies vaccine in North America, Asia & Latin America, thus fueling the growth of chick embryo cell rabies vaccine. Although chick embryo cell rabies vaccines are expensive, they are considered highly efficacious.

As per a study published by NCBI in 2014, globally, 55,000 people die from rabies every year out of which, 56% die in Asia and 44% die in Africa. Approximately 3.3 billion people are at risk of human infection mainly in Asia and Africa. The existing patient pool and the risk of infection with rabies are the major factors driving the chick embryo cell rabies vaccine market.

Global Chick Embryo Cell Rabies Vaccine Market: Drivers and Restraints

The rise in the number of stray animals in developing countries is expected to be the major factor, driving the growth of the global chick embryo cell rabies vaccine market over the forecast period.

Other factors, which are expected to fuel the growth of the global chick embryo cell rabies vaccine market in the next few decades include the search for novel routes of vaccine administration, an increase in the prevalence of animal bites, and awareness among the population.

However, less supply of chick embryo cell rabies vaccine in remote areas, and strict government rules regarding the safety and efficacy of the chick embryo cell rabies vaccine are the factors, which hinder the growth of global chick embryo cell rabies vaccine market during the forecast period.

Global Chick Embryo Cell Rabies Vaccine Market: Overview

The global market for chick embryo cell rabies vaccine is expected to generate significant revenue with huge growth over the forecast due to the high demand for chick embryo cell rabies vaccine for the treatment of infection caused by Rabies virus. Based on application, Pre-exposure prophylaxis of chick embryo cell rabies vaccine is preferred due to less cost compared to chick embryo cell rabies vaccine for Post-exposure prophylaxis.

Global Chick Embryo Cell Rabies Vaccine Market: Regional Outlook

Geographically, the global chick embryo cell rabies vaccine market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific Excluding Japan, Japan, and the Middle East & Africa.

North America is anticipated to remain a dominant market player in the global chick embryo cell rabies vaccine market with the largest share as the government arranged programs to eradicate Rabies from country compared to other regions.

Other factors, such as pet adoption, awareness among the population, rise in healthcare expenditure, and animal vaccination increase the growth in this region. Europe is expected to hold the second largest revenue share in the global chick embryo cell rabies vaccine market throughout the forecast period owing to the rise in the adoption of pets.

However rapid growth is expected from Asia-Pacific, due to an increase in the investment in the healthcare and research sector, attracting manufacturers with lots of possibilities to explore their business of chick embryo cell rabies vaccine.

Global Chick Embryo Cell Rabies Vaccine Market: Key Players

Chick embryo cell rabies vaccine manufacturers focus on improved precision with even better accuracy in targeting the radiation. The chick embryo cell rabies vaccine market is highly fragmented owing to the presence of a large number of domestic manufacturers.

Examples of some of the key players operating in the chick embryo cell rabies vaccine market are major manufacturers of chick embryo cell rabies vaccine, including GlaxoSmithKline Inc., Novartis, Sanofi Pasteur, and others.

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers an exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
• Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep., and Others), Rest of Europe
• CIS & Russia
• Japan
• APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
• Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)

Report Highlights:

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Segmentation of Chick Embryo Cell Rabies Vaccine Market Research

• By Application :

  • Pre-Exposure Prophylaxis (Intra-Dermal)
  • Post-Exposure Prophylaxis (Intra-Muscular)

• By Distribution :

  • Retail Pharmacies
  • Hospital Pharmacies
  • e-commerce

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa